What does IRIS (Immune Reconstitution Inflammatory Syndrome) mean in a patient with retroviral disease (RVD)?

IRIS in HIV/Retroviral Disease Patients

IRIS stands for Immune Reconstitution Inflammatory Syndrome, which represents a paradoxical inflammatory complication occurring when HIV-infected patients initiate antiretroviral therapy (ART) at low CD4 counts, manifesting as either unmasking of subclinical opportunistic infections or paradoxical worsening of known infections despite appropriate treatment. 1

Two Clinical Presentations of IRIS

IRIS manifests in two distinct patterns that clinicians must recognize:

1. Unmasking IRIS

• Occurs when ART reveals a previously subclinical opportunistic infection that was not diagnosed before starting therapy 1
• Common pathogens in the U.S. include:
  • Disseminated Mycobacterium avium complex
  • Tuberculosis
  • Cytomegalovirus retinitis
  • Pneumocystis pneumonia
  • Kaposi sarcoma 1

2. Paradoxical IRIS

• Develops when patients experience clinical worsening of a known, treated opportunistic infection after initiating ART 1
• The infection was appropriately treated with antimicrobials, yet inflammatory symptoms intensify after immune recovery begins

Pathophysiology

IRIS results from dysregulated immune recovery rather than treatment failure. The syndrome occurs as CD4+ T cells re-emerge and the immune system becomes hyperresponsive to pathogen antigens 2. This represents an exuberant, pathological inflammatory response during immune reconstitution rather than inadequate antimicrobial therapy 3, 4.

Key Risk Factors

The primary predictors for developing IRIS include:

• Low baseline CD4+ T-cell count (typically <50-100 cells/μL) 3
• Short interval between treating the opportunistic infection and starting ART 3
• High baseline viral load
• Rapid immune recovery after ART initiation

Clinical Significance and Morbidity

IRIS can cause considerable morbidity and occasionally mortality, particularly when tuberculosis or cryptococcal disease affects the central nervous system. 1, 3 The syndrome complicates clinical management and requires clinicians to distinguish between:

• True treatment failure
• Drug resistance
• New opportunistic infections
• IRIS-related inflammation

Management Approach

Continue ART in most cases while providing appropriate antimicrobial therapy for the underlying infection. 3 The general algorithm is:

1. Do NOT discontinue ART unless IRIS is life-threatening or overwhelming 4, 5
2. Continue or optimize antimicrobial therapy for the opportunistic infection
3. Consider corticosteroids for severe cases, particularly:
   • CNS involvement (TB meningitis, cryptococcal meningitis) 3, 6
   • Respiratory compromise
   • After excluding other conditions that could explain inflammatory manifestations 3
4. Most cases are self-limiting and resolve with supportive care 3, 5

Critical Pitfall to Avoid

The most common error is discontinuing ART when IRIS develops. The benefits of treating HIV infection outweigh the risks associated with IRIS 7. Stopping ART allows HIV replication to resume, CD4 counts to decline, and ultimately worsens patient outcomes. The presence of IRIS does not predict poor overall HIV treatment response 7.

Prevention Strategy

Initiating ART at CD4+ T-cell counts >350 cells/μL prevents most IRIS cases by avoiding the severe immunosuppression that predisposes to this syndrome 3. This underscores the importance of early HIV diagnosis and treatment initiation before advanced immunodeficiency develops.